Company: OPGN
Filing Date: 2025-10-31
Form Type: 10-Q
Source: 0001829126-25-008771
Chunk: 32

Company: OPGEN INC
Filing Date: 2025-10-31
Form: 10-Q
Item: Part I, Item 1
Chunk 32
---
 any activity pursuant to this JV Agreement.

    21

Note 12 – Subsequent Events

The Company evaluates subsequent events and transactions
that occur after the balance sheet date up to October 31, 2025, the date that these unaudited condensed consolidated financial statements
are issued.

Other than as disclosed in this Note and as may
be disclosed elsewhere in the notes to the accompanying unaudited condensed consolidated financial statements, there have been no subsequent
events that require adjustment or disclosure in the accompanying unaudited condensed consolidated financial statements.

22

Item 2. Management’s
Discussion and Analysis of Financial Condition and Results of Operations

The
following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with
the unaudited condensed consolidated financial statements and the accompanying notes thereto included in Part I, Item 1 of this quarterly
report on Form 10-Q. This discussion contains forward-looking statements, based on current expectations and related to future events and
our future financial performance, that involve risks and uncertainties. Our actual results may differ materially from those anticipated
in these forward-looking statements as a result of many important factors, including those set forth under Part II. Item 1A. “Risk
Factors” of this quarterly report on Form 10-Q and Part 1. Item 1A of our annual report on Form 10-K for the year ended December 31,
2024.

Overview

OpGen,
Inc. (“OpGen” or the “Company”) was incorporated in Delaware in 2001. On April 1, 2020, OpGen completed its
business combination transaction with Curetis N.V., a public company with limited liability under the laws of the Netherlands. As part
of the transaction, the Company acquired all the shares of Curetis GmbH, a private limited liability company organized under the laws
of the Federal Republic of Germany (“Curetis”), and certain other assets and liabilities of Curetis, including all its shares
of Ares Genetics GmbH (“Ares Genetics”). From inception through November 2023, the Company operated as a precision medicine
company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. The Company, along with its subsidiaries,
Curetis and Ares Genetics, developed and commercialized molecular microbiology solutions helping to guide clinicians with more rapid and
actionable information about life-threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug